US Bioscience Reports 'Encouraging' Data On Lodenosine
July 2
Dow Jones Newswires
NEW YORK -- U.S. Bioscience Inc. (UBS) said data
from the Phase I clinical trial of Lodenosine, its novel
anti-retroviral agent, were "encouraging."
In a press release Thursday, U.S. Bioscience said
Lodenosine, a purine-based reverse transcriptase
inhibitor, has shown activity against clinical isolates that
are resistant to other commercially available agents.
In the trial, which was sponsored by the National
Cancer Institute, Lodenosine showed anti-HIV activity
even in patients who had failed other anti-retroviral
therapies.
In one study, 25 patients with symptomatic HIV
infection and CD4 counts less than 500 cells/mm3 were
treated with 12 weeks of Lodenosine monotherapy.
In this study, the Lodenosine therapy was well tolerated
over 12 weeks, even in patients with substantial prior
anti-retroviral therapy.
U.S. Bioscience, West Conshohocken, Pa., develops
products for patients with cancer and AIDS.
NEW YORK (Dow Jones)--U.S. Bioscience Inc.
(UBS) said data from the Phase I clinical trial of
Lodenosine, its novel anti-retroviral agent, were
"encouraging."
In a press release Thursday, U.S. Bioscience said
Lodenosine, a purine-based reverse transcriptase
inhibitor, has shown activity against clinical isolates that
are resistant to other commercially available agents.
In the trial, which was sponsored by the National
Cancer Institute, Lodenosine showed anti-HIV activity
even in patients who had failed other anti-retroviral
therapies.
In one study, 25 patients with symptomatic HIV
infection and CD4 counts less than 500 cells/mm3 were
treated with 12 weeks of Lodenosine monotherapy.
In this study, the Lodenosine therapy was well tolerated
over 12 weeks, even in patients with substantial prior
anti-retroviral therapy.
U.S. Bioscience, West Conshohocken, Pa., develops
products for patients with cancer and AIDS.
|
